Medication info
Clorak Tablet (Acyclovir)

Clorak Tablet (Acyclovir)

Prescription medicationTabletIntravenous injection
Ingredient · strength
Acyclovir›200mg / 1 tablet
Manufacturer / importer
CTC Bio Co., Ltd.
Appearance
Light blue round tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201803418 · Approved 2018.08.21 · Insurance code 669502370

Summary

Main use
Treatment and prevention of herpes simplex; treatment of chickenpox and shingles in children
Who receives it
Adults · Children
Adult administration
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg five times daily at 4-hour intervals for 5 days. Treatment may be extended in cases of severe initial infection. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) It is preferable to start treatment as soon as possible after infection; in recurrent cases, treatment should preferably begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer this medicine at 200 mg four times daily, approximately 6 hours apart. Alternatively, it may be administered at 400 mg twice daily, 12 hours apart. 2) The dose may subsequently be reduced to 200 mg two or three times daily after confirming its efficacy. 3) To assess the natural course of the disease, treatment should be periodically discontinued in patients receiving long-term treatment every 6 ~ 12 months. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer this medicine at 200 mg four times daily, approximately 6 hours apart. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer this medicine at 800 mg five times daily, at approximately 4-hour intervals except during sleep, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunodeficiency or gastrointestinal malabsorption. 3) It is preferable to start treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance below 10 mL per minute), it is preferable to administer this medicine at 200 mg every 12 hours. 2. Treatment of herpes zoster virus infections 1) In patients with creatinine clearance below 10 mL per minute, it is preferable to reduce the dose to 800 mg twice daily, approximately 12 hours apart. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg three times daily, approximately 8 hours apart.
Child administration
○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients — 2 years and older: Use the adult dose. 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients — Under 2 years: Use 1/2 of the adult dose. 2. Treatment of chickenpox in children 2 years and older: Administer this medicine at 20 mg per kg of body weight per dose (maximum 800 mg per dose) four times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset.

Ingredients

Manufacturer
CTC Bio Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes simplex; treatment of chickenpox and shingles in children

  • Primary genital herpes
  • recurrent genital herpes
  • herpes simplex infections of skin and mucous membranes
  • shingles virus infections
  • acute pain
  • chickenpox
View approved original text

This medicine is used to treat and prevent infections caused by the herpes simplex virus in skin and mucous membranes, including primary and recurrent genital herpes. It is also effective in treating shingles virus infections and particularly helps relieve acute pain. It is used for the treatment of chickenpox and is suitable for children over 2 years old. However, the efficacy against postherpetic neuralgia has not yet been clearly demonstrated. Overall, this drug is used to improve symptoms through the treatment of various viral infections.

How it is given

Adult administration

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg five times daily at 4-hour intervals for 5 days. Treatment may be extended in cases of severe initial infection. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) It is preferable to start treatment as soon as possible after infection; in recurrent cases, treatment should preferably begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer this medicine at 200 mg four times daily, approximately 6 hours apart. Alternatively, it may be administered at 400 mg twice daily, 12 hours apart. 2) The dose may subsequently be reduced to 200 mg two or three times daily after confirming its efficacy. 3) To assess the natural course of the disease, treatment should be periodically discontinued in patients receiving long-term treatment every 6 ~ 12 months. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer this medicine at 200 mg four times daily, approximately 6 hours apart. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer this medicine at 800 mg five times daily, at approximately 4-hour intervals except during sleep, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunodeficiency or gastrointestinal malabsorption. 3) It is preferable to start treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance below 10 mL per minute), it is preferable to administer this medicine at 200 mg every 12 hours. 2. Treatment of herpes zoster virus infections 1) In patients with creatinine clearance below 10 mL per minute, it is preferable to reduce the dose to 800 mg twice daily, approximately 12 hours apart. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg three times daily, approximately 8 hours apart.

Child administration

○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients — 2 years and older: Use the adult dose. 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients — Under 2 years: Use 1/2 of the adult dose. 2. Treatment of chickenpox in children 2 years and older: Administer this medicine at 20 mg per kg of body weight per dose (maximum 800 mg per dose) four times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset.

Precautions

This medication should not be used by patients who have had allergic reactions to this drug or its ingredients, or to valacyclovir. Additionally, this medication contains lactose, so it should not be administered to patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Patients with poor kidney function should be cautious when using this medication as it may cause adverse reactions in the central nervous system. Patients with liver dysfunction should also be careful as there is a risk of worsening liver function when using this medication. Infants, children, and elderly patients should be particularly cautious when using this medication, and dosage and intervals should be adjusted appropriately. During treatment with this medication, severe allergic reactions such as anaphylaxis shock may rarely occur, so if symptoms such as difficulty breathing, decreased blood pressure, or chest tightness appear, treatment should be stopped immediately and medical help should be sought. Hypersensitivity reactions such as skin rash, fever, blisters, or urticaria may occur, so if such symptoms arise, discontinue use and consult a doctor. Rarely, various neurological symptoms such as hair loss, severe skin conditions, altered consciousness, confusion, seizures, drowsiness, tremors, and dizziness may occur, particularly more frequently in elderly patients or those with kidney disease. Multiple side effects have been reported such as decreased kidney function, blood disorders, liver function anomalies, gastrointestinal disturbances, muscle pain, arrhythmia, and urination problems, so any abnormal symptoms should be reported to a healthcare provider immediately. This medication is most effective when administered as soon as symptoms appear for herpes simplex and chickenpox, and for shingles, it should be started within 5 days after the appearance of skin symptoms and chickenpox within 3 days. Immunocompromised patients may consider intravenous treatment. During treatment with this medication, it is important to maintain adequate hydration to reduce the risk of dehydration and kidney toxicity. Patients with recurrent genital herpes should discuss with their physician whether to continue using this medication after one year of treatment. This medication may cause drowsiness or altered consciousness, so caution should be exercised when driving or operating hazardous machinery, especially for those with compromised kidney function. There may be interactions when used with other drugs, so caution is especially needed when used in conjunction with probenecid, cimetidine, theophylline, or mycophenolate mofetil. Women who are pregnant or may become pregnant should be cautious when using this medication, and nursing mothers should discontinue breastfeeding as this medication may pass into breast milk. In infants and children, it should be administered carefully in the minimum effective dose only when necessary, as safety in neonates and low-birth-weight infants has not been established. Elderly patients may have increased blood concentrations of this medicine due to reduced kidney function, so dosage and intervals should be adjusted, and adequate hydration is necessary. In cases of overdose, serious symptoms such as agitation, coma, seizures, and somnolence may occur, and it can cause kidney damage, requiring immediate medical observation and appropriate treatment. Blood dialysis may be required to control blood concentration.

Side effects

  • Anaphylactic shock
  • anaphylactic-like reactions
  • hypotension
  • dyspnea
  • chest tightness
  • phot hypersensitivity reactions
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 118 more
  • urticarial erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • mucous membrane syndrome
  • toxic epidermal necrolysis
  • alterations in consciousness
  • disorientation
  • impaired concentration
  • aggressive behavior
  • depersonalization
  • anxiety
  • coordination impairment
  • coma
  • confusion
  • delirium
  • stutter
  • encephalopathy
  • hallucinations
  • psychosis
  • seizures
  • drowsiness
  • tremors
  • agitation
  • forgetfulness
  • insomnia
  • anxiety
  • talking to oneself
  • paresthesia
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • dizziness
  • renal failure
  • crystalluria
  • increased BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • hemorrhage
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • upper abdominal pain
  • gastric pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • decreased appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • fatigue
  • overall lethargy
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • increased blood pressure
  • decreased blood pressure
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glycosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • hair loss
  • sweating
  • hyponatremia
  • low serum protein
  • increased total cholesterol
  • increased triglycerides
  • elevated serum potassium
  • decreased serum albumin
  • anxiety
  • coma
  • seizures
  • lethargy
  • confusion
  • hallucinations
  • agitation
  • epileptic seizures
  • comatose state

Not everyone experiences these, and they can vary from person to person.

Storage

Keep this medication in a tightly closed container to prevent air and moisture from entering. It is best stored in a cool and dry place below 25 degrees Celsius.

Appearance and packaging

Appearance

Light blue round tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.